NextGen Vaccines

NextGen Vaccines is a Danish vaccine biotechnology spin-out from the University of Copenhagen associated with the inventors of a proprietary capsid virus-like particle (cVLP) platform. The company appears to function primarily as the originating platform owner behind AdaptVac, a joint venture formed with ExpreS2ion Biotechnologies in 2017 to develop prophylactic and therapeutic vaccines. Public descriptions link the platform to vaccine and immunotherapy programs in infectious disease, oncology, and immunological disorders. Available public information suggests NextGen Vaccines itself is private, platform-oriented, and early stage, with most disclosed downstream pipeline activity housed in AdaptVac rather than under a separately visible standalone operating pipeline. The cVLP technology has been described as clinically Phase 3-validated, but that validation refers to the platform background rather than to a clearly disclosed proprietary late-stage NextGen Vaccines product pipeline.